These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25117093)

  • 1. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
    Davitt K; Babcock BD; Fenelus M; Poon CK; Sarkar A; Trivigno V; Zolkind PA; Matthew SM; Grin'kina N; Orynbayeva Z; Shaikh MF; Adler V; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
    Ann Clin Lab Sci; 2014; 44(3):241-8. PubMed ID: 25117093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.
    Thadi A; Gleeson EM; Khalili M; Shaikh MF; Goldstein E; Morano WF; Daniels LM; Grandhi N; Glatthorn H; Richard SD; Campbell PM; Sarafraz-Yazdi E; Pincus MR; Bowne WB
    Ann Clin Lab Sci; 2020 Sep; 50(5):611-624. PubMed ID: 33067207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
    Thadi A; Lewis L; Goldstein E; Aggarwal A; Khalili M; Steele L; Polyak B; Seydafkan S; Bluth MH; Ward KA; Styler M; Campbell PM; Pincus MR; Bowne WB
    Anticancer Res; 2020 Sep; 40(9):4857-4867. PubMed ID: 32878773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.
    Bowne WB; Sookraj KA; Vishnevetsky M; Adler V; Sarafraz-Yazdi E; Lou S; Koenke J; Shteyler V; Ikram K; Harding M; Bluth MH; Ng M; Brandt-Rauf PW; Hannan R; Bradu S; Zenilman ME; Michl J; Pincus MR
    Ann Surg Oncol; 2008 Dec; 15(12):3588-600. PubMed ID: 18931881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.
    Krzesaj P; Adler V; Feinman RD; Miller A; Silberstein M; Yazdi E; Pincus MR
    Ann Clin Lab Sci; 2024 Mar; 54(2):137-148. PubMed ID: 38802154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
    Sarafraz-Yazdi E; Bowne WB; Adler V; Sookraj KA; Wu V; Shteyler V; Patel H; Oxbury W; Brandt-Rauf P; Zenilman ME; Michl J; Pincus MR
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1918-23. PubMed ID: 20080680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.
    Sookraj KA; Bowne WB; Adler V; Sarafraz-Yazdi E; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):325-31. PubMed ID: 20182728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.
    Thadi A; Morano WF; Khalili M; Babcock BD; Shaikh MF; Foster DS; Piazza Y; Gleeson EM; Goldstein E; Steele L; Campbell PM; Lin BO; Pincus MR; Bowne WB
    Anticancer Res; 2021 Jan; 41(1):27-42. PubMed ID: 33419797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
    Sarafraz-Yazdi E; Mumin S; Cheung D; Fridman D; Lin B; Wong L; Rosal R; Rudolph R; Frenkel M; Thadi A; Morano WF; Bowne WB; Pincus MR; Michl J
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo.
    Michl J; Scharf B; Schmidt A; Huynh C; Hannan R; von Gizycki H; Friedman FK; Brandt-Rauf P; Fine RL; Pincus MR
    Int J Cancer; 2006 Oct; 119(7):1577-85. PubMed ID: 16688716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer peptides from ras-p21 and p53 proteins.
    Pincus MR; Fenelus M; Sarafraz-Yazdi E; Adler V; Bowne W; Michl J
    Curr Pharm Des; 2011; 17(25):2677-98. PubMed ID: 21728981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells.
    Li Y; Mao Y; Rosal RV; Dinnen RD; Williams AC; Brandt-Rauf PW; Fine RL
    Int J Cancer; 2005 May; 115(1):55-64. PubMed ID: 15645452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.
    Do TN; Rosal RV; Drew L; Raffo AJ; Michl J; Pincus MR; Friedman FK; Petrylak DP; Cassai N; Szmulewicz J; Sidhu G; Fine RL; Brandt-Rauf PW
    Oncogene; 2003 Mar; 22(10):1431-44. PubMed ID: 12629507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue of K562 cells from MDM2-modulated p53-dependent apoptosis by growth factor-induced differentiation.
    Mahdi T; Alcalay D; Cognard C; Tanzer J; Kitzis A
    Biol Cell; 1998 Dec; 90(9):615-27. PubMed ID: 10085538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.
    Pincus MR; Silberstein M; Zohar N; Sarafraz-Yazdi E; Bowne WB
    Biomedicines; 2024 May; 12(6):. PubMed ID: 38927351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule MDM2 inhibitor LQFM030-induced apoptosis in p53-null K562 chronic myeloid leukemia cells.
    de Oliveira Ribeiro H; Cortez AP; de Ávila RI; da Silva ACG; de Carvalho FS; Menegatti R; Lião LM; Valadares MC
    Fundam Clin Pharmacol; 2020 Aug; 34(4):444-457. PubMed ID: 32011031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
    Rosal R; Pincus MR; Brandt-Rauf PW; Fine RL; Michl J; Wang H
    Biochemistry; 2004 Feb; 43(7):1854-61. PubMed ID: 14967026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
    Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
    ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.
    Sarafraz-Yazdi E; Gorelick C; Wagreich AR; Salame G; Angert M; Gartman CH; Gupta V; Bowne WB; Lee YC; Abulafia O; Pincus MR; Michl J
    Ann Clin Lab Sci; 2015; 45(6):650-8. PubMed ID: 26663795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.